Tonic Motor Activation (TOMAC) Therapy in Patients With Restless Legs Syndrome and Dopaminergic Augmentation
A legfontosabb adatok
- Ki végzi
- Noctrix Health, Inc.
- Hol
- Ausztria1 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toborzás még nem indult
- Résztvevők
- 50 fő, tervezett
- Kezdés
- 2026. ápr.
- Várható befejezés
- 2027. jan.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Tonic Motor Activation (TOMAC) Device
- A regiszteradat frissítve
- 2026. február 9.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with moderate to severe restless legs syndrome (RLS) whose symptoms got worse on dopamine drugs (augmentation). Participants use a non-invasive nerve stimulation device on the leg.
- Életkor
- 18 years or older.
- Nem
- All sexes can join.
- A betegség stádiuma
- Moderate to severe RLS, IRLS score of 15 points or more. Dopaminergic augmentation with ASRS score of 5 points or more. Waking with RLS symptoms at least 3 nights per week in the past 30 days. Symptoms in the lower legs or feet are as bad as or worse than elsewhere.
- Korábbi kezelés
- Must be taking a stable dose and schedule of a dopamine agonist for the 4 weeks before joining, at least 25mg LEDD per day. No change in RLS medicine dose in the past 4 weeks. No IV iron in the past 6 months. Must agree not to change antidepressants or sleep medicines.
- Biomarker vagy leletérték
- Ferritin (iron store) must be at least 75 ng/mL, or the person must be willing to consider iron supplements.
A részvétel fő kizáró okai
- Taking medicines that worsen RLS, such as sedating antihistamines, SSRIs, SNRIs, tramadol or neuroleptics.
- Another sleep disorder that seriously disturbs sleep, or an irregular sleep schedule such as shift work.
- Stage 4-5 kidney disease, iron-deficiency anaemia, severe heart disease (NYHA class IV), Parkinson's disease, multiple sclerosis or other movement disorders.
- Epilepsy or seizures, metal implant in the upper fibula, or open sores where the device goes.
- Pregnant or trying to become pregnant.
A regiszter feltételei, szó szerint
Mind a 25 feltétel megnézéseKevesebb
Ki vehet részt
- Adult 18 years of age or older when written informed consent is obtained
- Diagnosis of restless legs syndrome confirmed by IRLSSG criteria
- Moderate-severe RLS, IRLS ≥15 points at study entry
- Dopaminergic augmentation based on clinician assessment and ASRS (augmentation severity rating scale) ≥5 points at study entry
- Subject agrees to not change the dose or schedule of antidepressants and sleep medications
- Currently taking stable dose and schedule of dopamine agonist over the 4 weeks prior to enrollment, with average daily dose >= 25mg Levodopa Equivalent Daily Dose (LEDD, https://pdmedcalc.co.uk/calculator)
- Patient reports ≥3 nights per week in the 30d prior to study entry: waking during the sleep period with RLS symptoms that interfered with sleep re-initiation
- RLS sensory symptoms in lower legs and/or feet are equally or more distressing than RLS sensory symptoms in all other anatomical locations
- The subject possesses the necessary equipment, internet/phone accessibility, and communication ability to complete electronic questionnaires and respond to electronic communications and phone calls from the research staff throughout the in-home portion of the study
- The subject has signed a valid, IRB-approved informed consent form and can understand the requirements of the study and instructions for device usage
Ki nem vehet részt
- IV iron supplementation in the 6 months prior to study entry
- Change to dose of RLS prescription medication(s) in the 4 weeks prior to study entry
- Medications that are known to exacerbate RLS symptoms, including: Sedative antihistamines, Tri/tetracyclics, MAOIs, SSRIs and SNRIs, Tramadol, Neuroleptics, Antiemetics, or the anticonvulsants Phenytoin or Methsuximid
- Change in medication that is known to affect RLS symptoms in the 4 weeks prior to study entry (e.g. sleep medication, antihistamines, antidepressants)
- During the initial investigational device titration process, sensation threshold >= 30mA or distraction threshold < 15mA, or the device does not properly fit the subject
- One or more of the following contraindications to the investigational device: Diagnosis of epilepsy or other seizure disorder, Metal implant in upper fibula, Known allergy to device materials (or severe previous reaction to medical adhesives or bandages), Open sores, or injury at or near the location of therapy device application
- Subject is using another investigational device or drug during the study
- Primary sleep disorder other than RLS that significantly interferes with sleep at the time of screening visit (e.g. obstructive sleep apnea with adherent CPAP usage would not be an exclusion but typical sleep onset latency of >60min on nights without RLS symptoms would be an exclusion)
- One or more of the following confounding comorbidities: Stage 4-5 chronic kidney disease or renal failure , Iron-deficient anemia, Severe cardiac disease (NYHA class IV), Movements disorder other than RLS (Parkinson's disease, Huntington's disease, dyskinesia, dystonia), Multiple Sclerosis , Moderate-severe cognitive disorder (MoCA<26) or mental illness, Moderate-severe edema affecting the lower legs
- Medical condition not listed above that may affect validity of the study or put the subject at risk as determined by the investigator
- Baseline ferritin <75 ng/mL or patient is unwilling to consider iron supplementation
- Irregular sleep schedule: subject reports that bedtime is typically outside of 21:00 - 03:00 or reports that bedtime regularly varies by more than 4 hours, such as due to shift work
- Subject has neuropathy and is unable to clearly distinguish between symptoms of neuropathy and symptoms of RLS
- Known to be pregnant or trying to become pregnant
- Subject does not understand the study requirements or device instructions, does not have the ability to complete the study assessments, or is unable or unwilling to comply with study requirements
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study evaluates Tonic Motor Activation (TOMAC) therapy in adults with restless legs syndrome and dopaminergic augmentation. Participants use a noninvasive peroneal nerve stimulation device over a defined treatment period to assess symptom response and medication use.
A vizsgálat csoportja
- TOMAC TherapyA vizsgált kezelés
Participants receive Tonic Motor Activation (TOMAC) therapy using noninvasive peroneal nerve stimulation with investigational settings and are followed over a defined treatment period.
Kezelés: Tonic Motor Activation (TOMAC) Device
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Evaluating Response to Tonic Motor Activation (TOMAC) Therapy for Patients With Restless Legs Syndrome and Dopaminergic Augmentation
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. február 9.